Eli Lilly launches Mounjaro, the much-awaited diabetes drug, in India. It is priced at ₹3,500 for 2.5 mg. Mounjaro and Ozempic, another popular obesity drug, differ in active ingredients. Let’s take a look at how both drugs tackle type 2 diabetes.

The global weight-loss drug market is expected to reach $150 billion in the next decade. By 2026, semaglutide (the active ingredient in Wegovy and Ozempic) will go off-patent in India, allowing local firms to introduce cheaper alternatives.

Global pharmaceutical company Eli Lilly has launched Mounjaro (tirzepatide) in India. The drug, a single-molecule drug designed to bind to and activate both GIP and GLP-1 receptors, helps in regulating regulate blood sugar and metabolism.